ES2154261T3 - Nuevo uso de difenilbutil-piperazincarboxamidas en el tratamiento de trastornos por abuso de sustancias. - Google Patents

Nuevo uso de difenilbutil-piperazincarboxamidas en el tratamiento de trastornos por abuso de sustancias.

Info

Publication number
ES2154261T3
ES2154261T3 ES92907159T ES92907159T ES2154261T3 ES 2154261 T3 ES2154261 T3 ES 2154261T3 ES 92907159 T ES92907159 T ES 92907159T ES 92907159 T ES92907159 T ES 92907159T ES 2154261 T3 ES2154261 T3 ES 2154261T3
Authority
ES
Spain
Prior art keywords
abuse
piperazincarboxamidas
difenilbutil
disorders
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907159T
Other languages
English (en)
Inventor
Anders Bjork
Erik Christensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2154261T3 publication Critical patent/ES2154261T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

NUEVO USO DE CIERTAS DIFENILBUTIL-PIPERAZINACARBOXAMIDAS, ESPECIALMENTE DE AMPEROZIDA, 4-[4,4-BIS(4-FLUOROFENIL)BUTIL]-NETIL-1-PIPERAZINACARBOXAMIDA Y SALES DE LAS MISMAS, EN EL TRATAMIENTO DE TRASTORNOS POR ABUSO DE SUSTANCIAS. DE MANERA MAS CONCRETA, ESTE TRATAMIENTO SE REFIERE A LA MEJORA DE LOS SINTOMAS DE ABSTINENCIA Y A LA MODIFICACION DEL COMPORTAMIENTO EN BUSQUEDA DE DROGAS.
ES92907159T 1991-03-22 1992-03-23 Nuevo uso de difenilbutil-piperazincarboxamidas en el tratamiento de trastornos por abuso de sustancias. Expired - Lifetime ES2154261T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use

Publications (1)

Publication Number Publication Date
ES2154261T3 true ES2154261T3 (es) 2001-04-01

Family

ID=20382242

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907159T Expired - Lifetime ES2154261T3 (es) 1991-03-22 1992-03-23 Nuevo uso de difenilbutil-piperazincarboxamidas en el tratamiento de trastornos por abuso de sustancias.

Country Status (24)

Country Link
US (2) US5434156A (es)
EP (1) EP0538422B1 (es)
JP (1) JP3221611B2 (es)
KR (1) KR100196674B1 (es)
AT (1) ATE199057T1 (es)
AU (1) AU653797B2 (es)
BG (1) BG61829B1 (es)
BR (1) BR9204969A (es)
CA (1) CA2083505C (es)
CZ (1) CZ282222B6 (es)
DE (1) DE69231680T2 (es)
DK (1) DK0538422T3 (es)
EE (1) EE02973B1 (es)
ES (1) ES2154261T3 (es)
GR (1) GR3035805T3 (es)
HU (2) HU217833B (es)
IE (1) IE920920A1 (es)
NO (1) NO301311B1 (es)
PT (1) PT100279B (es)
RO (1) RO109702B1 (es)
RU (1) RU2095062C1 (es)
SE (1) SE9100860D0 (es)
SK (1) SK279237B6 (es)
WO (1) WO1992016211A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
ATE338575T1 (de) * 2001-01-17 2006-09-15 Hythiam Inc Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
ES2287255T3 (es) * 2001-02-15 2007-12-16 Hythiam, Inc. Uso de flumazenil para producir un medicamento parta el tratamiento de la dependencia a cocaina.
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
CA2563743A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0712039A2 (pt) * 2006-05-09 2011-12-20 Boehringer Ingelheim Int uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
BRPI0716436B8 (pt) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
HU9203632D0 (en) 1993-03-29
JPH05507731A (ja) 1993-11-04
NO301311B1 (no) 1997-10-13
PT100279A (pt) 1993-07-30
SK279237B6 (sk) 1998-08-05
CA2083505C (en) 2003-06-10
JP3221611B2 (ja) 2001-10-22
NO924502L (no) 1992-11-23
SK344992A3 (en) 1995-11-08
SE9100860D0 (sv) 1991-03-22
KR100196674B1 (ko) 1999-06-15
BG97108A (bg) 1994-03-24
NO924502D0 (no) 1992-11-23
DK0538422T3 (da) 2001-05-07
BG61829B1 (bg) 1998-07-31
RU2095062C1 (ru) 1997-11-10
US5618817A (en) 1997-04-08
EP0538422B1 (en) 2001-02-07
WO1992016211A1 (en) 1992-10-01
RO109702B1 (ro) 1995-05-30
KR930700108A (ko) 1993-03-13
GR3035805T3 (en) 2001-07-31
PT100279B (pt) 1999-06-30
CZ282222B6 (cs) 1997-06-11
CA2083505A1 (en) 1992-09-23
ATE199057T1 (de) 2001-02-15
AU1428092A (en) 1992-10-21
IE920920A1 (en) 1992-09-23
CZ344992A3 (en) 1994-02-16
AU653797B2 (en) 1994-10-13
DE69231680T2 (de) 2001-06-07
BR9204969A (pt) 1993-07-27
DE69231680D1 (de) 2001-03-15
HUT64696A (en) 1994-02-28
EP0538422A1 (en) 1993-04-28
EE02973B1 (et) 1997-04-15
HU217833B (hu) 2000-04-28
US5434156A (en) 1995-07-18

Similar Documents

Publication Publication Date Title
GR3035805T3 (en) New use of diphenylbutylpiperazinecarboxamides in the treatment of substance disorders.
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
ATE226436T1 (de) Neue verwendung von dexmedetomidin
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
KR100321319B1 (ko) 물질남용장애를치료하는방법및제약학적조성물
DE69629195D1 (de) Inhibitor von gehirnödemen
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
NO982463L (no) Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
ATE207357T1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
NZ332484A (en) use of pyridyl and pyrimidyl substituted piperazine derivatives for treating substance abuse disorders
KR940011006A (ko) 황금추출물을 유효성분으로 하는 치주질환예방 및 치료제 조성물
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
KR940003550A (ko) 노인성 치매 예방 및 치료방법
CA2123853A1 (en) Smoking Suppressant and Method of Application Thereof

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19930319

FG2A Definitive protection

Ref document number: 538422

Country of ref document: ES